7-Diethylamino-3(2′-benzoxazolyl)-coumarin is a novel microtubule inhibitor with antimitotic activity in multidrug resistant cancer cells

Biochemical Pharmacology

Volumn 77, Issue 12, 2009, Pages 1773-1779

  Kim, Su Nam ^a   Kim, Nam Hyun ^b   Park, Yeon Sook ^b   Kim, Hanna ^b   Lee, Seokjoon ^b   Wang, Qian ^c   Kim, Yong Kee ^b  

^a Korea Institute of Science and Technology   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

7 Diethylamino 3(2 benzoxazolyl) coumarin; Microtubule; Multidrug resistance

Indexed keywords

7 DIETHYLAMINO 3 (2' BENZOXAZOLYL)COUMARIN DERIVATIVE; AURORA A KINASE; AURORA B KINASE; COUMARIN DERIVATIVE; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; FIBROBLAST; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MITOSIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

AMINOCOUMARINS; ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOXAZOLES; CELL CYCLE; CELL LINE, TUMOR; COUMARINS; DRUG RESISTANCE, NEOPLASM; G2 PHASE; HUMANS; INHIBITORY CONCENTRATION 50; MICROTUBULES; TUBULIN MODULATORS;

EID: 67349212426     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.03.007     Document Type: Article

References (23)

1. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 4 (2004) 253-265
2. Nogales E. Structural insights into microtubule function. Annu Rev Biochem 69 (2000) 277-302
3. Bhat K.M., and Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 13 (2007) 2849-2854
4. Checchi P.M., Nettles J.H., Zhou J., Snyder J.P., and Joshi H.C. Microtubule-interacting drugs for cancer treatment. Trends Pharmacol Sci 24 (2003) 361-365
5. Jackson J.R., Patrick D.R., Dar M.M., and Huang P.S. Targeted anti-mitotic therapies: can we improve on tubulin agents?. Nat Rev Cancer 7 (2007) 107-117
6. Pellegrini F., and Budman D.R. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 23 (2005) 264-273
7. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 (2002) 48-58
8. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., and Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 22 (2003) 7468-7485
9. Miglarese M.R., and Carlson R.O. Development of new cancer therapeutic agents targeting mitosis. Expert Opin Investig Drugs 15 (2006) 1411-1425
10. Kuppens I.E. Current state of the art of new tubulin inhibitors in the clinic. Curr Clin Pharmacol 1 (2006) 57-70
11. Fornier M.N. Ixabepilone, first in a new class of antineoplastic agents: the natural epothilones and their analogues. Clin Breast Cancer 7 (2007) 757-763
12. Thompson C.A. FDA approves new breast cancer treatment. Am J Health Syst Pharm 64 (2007) 2406
13. Lee S., Sivakumar K., Shin W.S., Xie F., and Wang Q. Synthesis and anti-angiogenesis activity of coumarin derivatives. Bioorg Med Chem Lett 16 (2006) 4596-4599
14. Kim Y.K., Song Y.J., Seo D.W., Kang D.W., Lee H.Y., Rhee D.K., et al. Reversal of multidrug resistance by 4-chloro-N-(3-((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)phenyl)benzamide through the reversible inhibition of P-glycoprotein. Biochem Biophys Res Commun 355 (2007) 136-142
15. King K.L., and Cidlowski J.A. Cell cycle and apoptosis: common pathways to life and death. J Cell Biochem 58 (1995) 175-180
16. Norbury C., and Nurse P. Animal cell cycles and their control. Annu Rev Biochem 61 (1992) 441-470
17. Bassermann F., Peschel C., and Duyster J. Mitotic entry: a matter of oscillating destruction. Cell Cycle 4 (2005) 1515-1517
18. Marumoto T., Zhang D., and Saya H. Aurora-A-a guardian of poles. Nat Rev Cancer 5 (2005) 42-50
19. Carvajal R.D., Tse A., and Schwartz G.K. Aurora kinases: new targets for cancer therapy. Clin Cancer Res 12 (2006) 6869-6875
20. Vader G., Medema R.H., and Lens S.M. The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol 173 (2006) 833-837
21. Keen N., and Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4 (2004) 927-936
22. Littlepage L.E., Wu H., Andresson T., Deanehan J.K., Amundadottir L.T., and Ruderman J.V. Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A. Proc Natl Acad Sci USA 99 (2002) 15440-15445
23. Crosio C., Fimia G.M., Loury R., Kimura M., Okano Y., Zhou H., et al. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol 22 (2002) 874-885